Nurmemmedov Lab
Laboratory of Preclinical Pharmacology of Novel Therapeutics
Principal Investigator: Elmar Nurmemmedov, PhD, MBA
Publications
Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia.
Barreyro L, Sampson AM, Ishikawa C, Hueneman KM, Choi K, Pujato MA, Chutipongtanate S, Wyder M, Haffey WD, O'Brien E, Wunderlich M, Ramesh V, Kolb EM, Meydan C, Neelamraju Y, Bolanos LC, Christie S, Smith MA, Niederkorn M, Muto T, Kesari S, Garrett-Bakelman FE, Bartholdy B, Will B, Weirauch MT, Mulloy JC, Gul Z, Medlin S, Kovall RA, Melnick AM, Perentesis JP, Greis KD, Nurmemmedov E, Seibel WL, Starczynowski DT.Sci Transl Med. 2022 Mar 9;14(635):eabb7695. doi: 10.1126/scitranslmed.abb7695. Epub 2022 Mar 9.PMID: 35263148
The miR-181a-SFRP4 Axis Regulates Wnt Activation to Drive Stemness and Platinum Resistance in Ovarian Cancer.
Belur Nagaraj A, Knarr M, Sekhar S, Connor RS, Joseph P, Kovalenko O, Fleming A, Surti A, Nurmemmedov E, Beltrame L, Marchini S, Kahn M, DiFeo A.Cancer Res. 2021 Apr 15;81(8):2044-2055. doi: 10.1158/0008-5472.CAN-20-2041. Epub 2021 Feb 11.PMID: 33574092 Free PMC article.
Antibody drug conjugates: Progress, pitfalls, and promises.
Mukherjee A, Waters AK, Babic I, Nurmemmedov E, Glassy MC, Kesari S, Yenugonda VM.Hum Antibodies. 2019;27(1):53-62. doi: 10.3233/HAB-180348.PMID: 30223393 Review.
WNT Signaling as a Therapeutic Target for Glioblastoma.
Latour M, Her NG, Kesari S, Nurmemmedov E.Int J Mol Sci. 2021 Aug 5;22(16):8428. doi: 10.3390/ijms22168428.PMID: 34445128 Free PMC article. Review.